| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA543: Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs |
|
Medicine details |
|
| Medicine name | tofacitinib (Xeljanz®) |
| Formulation | 5 mg tablet |
| Reference number | 2286 |
| Indication | In combination with methotrexate for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior disease‑modifying antirheumatic drug therapy |
| Company | Pfizer Ltd |
| BNF chapter | Musculoskeletal & joint diseases |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 20/06/2018 |
| NICE guidance | TA543: Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs |